Immortal Dragons
- Company typePrivate
- Founded2015
- HeadquartersSingapore, Singapore
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Immortal Dragons does
Immortal Dragons is a privately held, purpose-driven longevity investment fund headquartered in Biopolis, Singapore, founded by Boyang Wang. The firm operates a $40 million fund dedicated to radical life-extension technologies, guided by a 'Replace Not Repair' thesis that prioritizes organ replacement, 3D bioprinting, gene therapy, and artificial womb approaches over incremental repair-oriented therapeutics. Its disclosed portfolio is concentrated in four early-stage biotechs: R3 Bio (US-based, developing non-sentient 'bodyoid' organ sacks alongside Tim Draper and LongGame Ventures), Unlimited Bio (dual AAV9-Follistatin + VEGF plasmid gene therapy with a registered Phase 1/2a trial in Honduras' Próspera ZEDE), Frontier Bio (3D biofabrication of vascular and organ-scale tissue), and Etheros Pharmaceuticals (water-soluble fullerene-based catalytic antioxidants based in Singapore).
The fund's competitive positioning is built on Singapore's regulatory environment, which it leverages to source and support exploratory biomedical research that faces higher barriers in Western jurisdictions. Beyond direct investment, Immortal Dragons operates an active ecosystem-buildout program: it produces two podcast series (Immortal Dragons and Long Talk), translates and publishes longevity-related books, sponsors industry conferences and academic institutions, and maintains a presence across YouTube, LinkedIn, Spotify, Bilibili, Xiaohongshu, and WeChat to reach both English- and Chinese-speaking longevity audiences. The firm distributes capital exclusively through direct private investment rounds into portfolio companies; it does not sell products or services, and there is no disclosed pricing, fee schedule, or revenue figure.
Financially, Immortal Dragons remains early-stage. The fund vehicle was formally launched in July 2025 and is actively deploying across at least four portfolio companies, with founder Boyang Wang serving as the principal public face — including a Financial Times Tech Tonic podcast appearance in early 2026 and recurring thought-leadership contributions to Cell & Gene, Longevity.Technology, and the U.S. Transhumanist Party. Headcount and revenue are not publicly disclosed, and the firm's economics are those of a sub-$50M emerging fund: management fees only, no realized carry, and key-person concentration around the founder.
Immortal Dragons firmographics
Firmographics- Name
- Immortal Dragons
- Legal name
- Immortal Dragons
- Website
- https://id.life
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Immortal Dragons industry classification
Industry- Product category
- Longevity Venture Capital
- NAICS
- Funds, Trusts, and Other Financial Vehicles (525), Other Investment Pools and Funds (5259)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- SDG / Thematic Sustainable Investment Funds (FSANAJAN)
- akta.pro secondary industry
- Sustainable/Thematic Investing (Climate, Clean Tech, Water, Biodiversity) (FSAAALAB)
Keywords
Where Immortal Dragons is headquartered
LocationHeadquarters
- HQ city
- Singapore
- HQ country
- Singapore
- HQ region
- Asia
Offices2 records
Markets served
Immortal Dragons business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Fund Management / Investment Returns: As a $40 million longevity investment fund, Immortal Dragons generates returns through equity investments in biotech companies developing longevity technologies. The fund takes equity stakes in portfolio companies including R3 Bio, Unlimited Bio, Frontier Bio, and Etheros Pharmaceuticals.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Fund management - $40 million longevity fund |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Immortal Dragons product offering
Product offeringCore offering
Immortal Dragons is a purpose-driven longevity investment fund based in Singapore that deploys capital into biotech companies developing radical life-extension technologies. The fund targets breakthrough areas mainstream investors avoid, including organ replacement, 3D bioprinting, gene therapies, and artificial womb research, with a portfolio spanning xenotransplantation and regenerative medicine.
Product overview
Immortal Dragons is a purpose-driven longevity investment fund headquartered in Biopolis, Singapore. The fund focuses on investing in breakthrough longevity technologies including organ replacement strategies, 3D bioprinting, gene therapy, and artificial wombs. Beyond investments, the organization supports longevity science through publishing translated books, funding industry conferences and academic institutions, and producing podcasts and media content to promote anti-aging research and longevity concepts.
Differentiator
Problem solved
Functional benefit
Brands
- 不朽真龙 Immortal Dragons (Podcast): The company's main podcast series covering longevity science, featuring expert interviews, translations of international longevity research, and discussions on aging and life extension.
- 龙门阵 Long Talk
Products and services
- Immortal Dragons $40 Million Longevity Investment Fund
- Immortal Dragons Podcast (不朽真龙 Podcast)
Quantifiable outcome
- Fund invests in companies addressing organ transplant market exceeding $12 billion annually (Frontier Bio)
- +1 more outcomes
Companies that use Immortal Dragons
Customer profileNamed customers4 records
Segments1 record
Ideal customer profiles1 record
Immortal Dragons technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Immortal Dragons partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Jean Hébert / ARPA-HminorR3 Bio's founder John Schloendorn has an informal collaboration with Jean Hébert, a program manager at ARPA-H (Advanced Research Projects Agency for Health), on body replacement technology. ARPA-H is a U.S. government agency funding health research.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Immortal Dragons competitors and assessment
Company assessmentDirect peers
- BOLD Capital Partners: US-based venture fund with explicit focus on longevity, AI, and exponential technologies. Direct peer as a thesis-driven fund backing transformative life-extension and biotech ventures.
- The Longevity Fund: Laura Deming's venture fund focused on early-stage longevity biotech, one of the pioneering longevity VCs. Directly comparable as a specialist, thesis-driven fund investing in companies extending human healthspan and lifespan.
- Kizoo Technology Ventures: German longevity-focused VC fund (part of the Forever Healthy Foundation) backing rejuvenation biotech startups. Direct peer as a thematic longevity fund pursuing similar 'repair the damage' / replacement-style theses.
- Apeiron Investment Group: Hong Kong-based family office/biotech investor (Christian Angermayer) focused on longevity and psychedelic medicine. Direct peer as an Asia-anchored thematic investor in radical longevity ventures.
- Juvenescence: Public-markets-facing longevity biotech company and investor building a portfolio of therapeutic assets targeting aging. Directly comparable as a dedicated longevity investor with both fund-style and operating-company exposure.
- Formic Ventures: Longevity-focused venture fund investing in early-stage biotech companies targeting aging mechanisms. Direct peer in the small, specialized niche of longevity VC.
- Longevity Vision Fund: Sergey Young's $100M longevity-focused venture fund backing healthspan and life-extension technologies. Most directly comparable to Immortal Dragons as a thematic, purpose-driven VC fund targeting radical longevity outcomes.
Broad incumbents
- Hevolution Foundation: Saudi Arabia-backed foundation deploying over $1B annually into geroscience and longevity research. Broad incumbent as a much larger, well-capitalized player operating in the same longevity investment universe.
Emerging players
- VitaDAO: Decentralized autonomous organization funding early-stage longevity research via community-governed token treasury. Emerging peer because while structure differs, the mandate (funding radical longevity science ignored by mainstream capital) is highly analogous.
- Methuselah Fund: Non-profit-backed longevity investment vehicle funding tissue engineering and organ replacement startups. Emerging peer as a mission-aligned capital provider in the same radical-replacement thesis space.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Immortal Dragons social profiles
Digital presenceImmortal Dragons financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immortal Dragons leadership team
Management profileNumber of profiles
Profiles1 record
Immortal Dragons funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immortal Dragons M&A and investment
M&A and investmentM&A
Investments6 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immortal Dragons
What does Immortal Dragons do?
Immortal Dragons is a purpose-driven longevity investment fund based in Singapore that deploys capital into biotech companies developing radical life-extension technologies. The fund targets breakthrough areas mainstream investors avoid, including organ replacement, 3D bioprinting, gene therapies, and artificial womb research, with a portfolio spanning xenotransplantation and regenerative medicine.
Is Immortal Dragons a public or private company?
Immortal Dragons is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Immortal Dragons founded?
Immortal Dragons was founded in 2015. It employs 1 to 10 people.
Where is Immortal Dragons based?
Immortal Dragons is headquartered in Singapore, Singapore, in the Asia region.
How does Immortal Dragons make money?
One revenue line is on record: fund Management / Investment Returns.
Who are Immortal Dragons's main competitors?
Direct peers on record are BOLD Capital Partners, The Longevity Fund, Kizoo Technology Ventures, Apeiron Investment Group, Juvenescence, Formic Ventures and Longevity Vision Fund. Hevolution Foundation is listed as a broad incumbent. Emerging players are VitaDAO and Methuselah Fund.
Does Immortal Dragons have an API?
No public API is recorded for Immortal Dragons.
What industry is Immortal Dragons in?
Immortal Dragons's product category is Longevity Venture Capital. Its primary akta.pro industry code is FSANAJAN, SDG / Thematic Sustainable Investment Funds, with a secondary code of FSAAALAB, Sustainable/Thematic Investing (Climate, Clean Tech, Water, Biodiversity). Its NAICS code is 525 and its SIC code is 6282.